Tag : red blood cell-transfusion independence

CONFERENCE UPDATE

Early initiation of luspatercept derives greater benefit in ESA-naive TD LR-MDS: Post-hoc analysis of the phase 3 COMMANDS trial
Early initiation of luspatercept outperformed epoetin alfa in ESA-naïve, transfusion-dependent lower-risk myelodysplastic syndromes, achieving higher red blood celltransfusion independence ≥12-week rates and higher erythroid hematologic improvement. The benefit was greatest in less advanced disease, with longer and more durable responses.